Skip to main content

Table 2 Treatments received by LOT

From: Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Treatment, n (%)

1LOT

2LOT

3LOT

Received treatment

652

184

18

Sunitinib

396 (60.7%)

1 (0.5%)

Originally prescribed

375 (57.5%)

1 (0.5%)

Pazopanib intolerant

21 (3.2%)

Pazopanib

246 (37.7%)

Originally prescribed

209 (32.1%)

Sunitinib intolerant

37 (5.7%)

Axitinib

105 (57.1%)

4 (22.2%)

Everolimus

4 (0.6%)

77 (41.9%)

13 (72.2%)

Other

6 (0.9%)

1 (0.5%)

1 (5.6%)

On treatment at FU

140 (21.5%)

48 (26.1%)

6 (33.3%)

  1. LOT Line of therapy, FU Follow-Up